Sesen Bio Inc
Change company Symbol lookup
Select an option...
SESN Sesen Bio Inc
SII Sprott Inc
GDRX Goodrx Holdings Inc
OXM Oxford Industries Inc
BV Brightview Holdings Inc
ARKG ARK Genomic Revolution ETF
BWA Borgwarner Inc
RCG RENN Global Entrepreneurs Fund, Inc.
SPI SPI Energy Co Ltd
CLH Clean Harbors Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Sesen Bio, Inc. is a late-stage clinical company providing targeted fusion protein therapeutics (TFPTs) for the treatment of patients with cancer. Its product pipeline includes Vicinium, which is composed of an anti-epithelial cell adhesion molecule (EpCAM) antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The Company's product candidates are based on its TFPT platform and are focused on addressing areas of unmet medical need in cancer. TFPTs are single protein therapeutics composed of targeting domains genetically fused via peptide linkers to cytotoxic protein payloads that are produced through its recombinant one-step, microbial manufacturing process.

Price
Delayed
$0.9738
Day's Change
0.0609 (6.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9777
Day's Low
0.92
Volume
(Heavy Day)

Today's volume of 1,338,835 shares is on pace to be much greater than SESN's 10-day average volume of 4,371,546 shares.

1,338,835
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.